Increasing Mirtazapine to 15mg in Bipolar II with Anxiety
Yes, it is reasonable to increase mirtazapine from 7.5mg to 15mg in this clinical scenario, but proceed with caution given the patient's current mood state and ensure lithium optimization first.
Rationale for Dose Increase
The FDA-approved dosing for mirtazapine starts at 15mg daily, with the current 7.5mg dose being subtherapeutic 1. According to the drug label, the recommended starting dose is 15mg once daily, preferably in the evening, with dose increases up to 45mg as needed 1. The patient has been on 7.5mg for over 2 months, which is sufficient time to assess tolerability but insufficient for therapeutic effect on anxiety or mood symptoms.
Mirtazapine is described in guidelines as "potent and well tolerated; promotes sleep, appetite, and weight gain" with a maximum dose of 30mg at bedtime 2. The current presentation of anxiety, anger, irritability, and emotional lability suggests inadequate mood stabilization rather than antidepressant-induced activation.
Critical Safety Considerations
Risk of Mood Destabilization
The primary concern is whether this patient is experiencing a mixed or hypomanic state versus anxiety in the context of depression. The FDA label explicitly warns that mirtazapine may cause "mania or hypomania (manic episodes) in people who have a history of bipolar disorder" with symptoms including increased energy, racing thoughts, severe trouble sleeping, reckless behavior, and excessive irritability 1.
However, research suggests low doses of mirtazapine (used for sleep/sedation) carry minimal risk of manic switch, particularly when combined with a mood stabilizer 3. A systematic review found that low doses of mirtazapine were observed to cause mania only in patients with other risk factors, and when combined with mood stabilizers, the risk appears minimal 3.
Lithium Level Optimization
The lithium level of 0.6 mEq/L is at the lower end of the therapeutic range. Guidelines for bipolar disorder in adolescents note that lithium is FDA-approved down to age 12 for acute mania and maintenance 4. For maintenance treatment in adults, therapeutic levels of 0.2-0.6 mEq/L may be adequate 2, but for acute mood symptoms, higher levels (typically 0.8-1.2 mEq/L) are often needed.
Before increasing mirtazapine, strongly consider optimizing the lithium level first, as the current irritability, anger, and emotional lability may represent inadequate mood stabilization rather than anxiety requiring higher antidepressant doses.
Clinical Algorithm
Step 1: Assess Current Mood State
- If hypomanic/mixed features predominate (decreased need for sleep, increased goal-directed activity, pressured speech): Do NOT increase mirtazapine; optimize lithium first
- If anxiety/depression predominate (normal sleep need, low energy, no racing thoughts): Proceed with mirtazapine increase
Step 2: Optimize Mood Stabilizer
Given the current presentation of irritability and emotional lability, consider increasing lithium to 0.8-1.0 mEq/L before adjusting antidepressants, as guidelines emphasize that antidepressants should only be used as adjuncts when adequate mood stabilization is achieved 4.
Step 3: If Proceeding with Mirtazapine Increase
- Increase to 15mg nightly (the FDA-recommended starting dose) 1
- Monitor closely for signs of mood destabilization over 1-2 weeks
- Watch specifically for: decreased sleep need, increased energy, racing thoughts, increased impulsivity 1
- The dose change interval should be at least 1-2 weeks 1
Monitoring Requirements
Per the FDA label, monitor for 1:
- Activation of mania/hypomania: greatly increased energy, racing thoughts, reckless behavior, severe trouble sleeping
- Serotonin syndrome (though risk is low with mirtazapine monotherapy plus lithium)
- Sedation and functional impairment
- Weight gain and increased appetite (common side effects)
Common Pitfalls to Avoid
Mistaking a mixed state for anxiety: The combination of anxiety, anger, irritability, and emotional lability could represent a mixed/dysphoric state rather than pure anxiety, which would be better addressed by optimizing lithium rather than increasing antidepressant dose
Inadequate mood stabilizer coverage: Guidelines consistently emphasize that antidepressants in bipolar disorder should only be used with adequate mood stabilizer therapy 4. A lithium level of 0.6 may be insufficient for the current mood instability
Using subtherapeutic antidepressant doses long-term: While 7.5mg may help with sleep, it provides minimal antidepressant or anxiolytic effect. If an antidepressant is indicated, use therapeutic doses (15-45mg for mirtazapine) 2, 1
Ignoring cardiac considerations: While mirtazapine has minimal cardiac effects compared to other antidepressants 5, lithium can cause bradycardia and conduction abnormalities 5, so be aware of cumulative cardiac risk
Alternative Considerations
If anxiety remains the primary target and mood destabilization is a concern, consider:
- Optimizing lithium alone first
- Adding an atypical antipsychotic (quetiapine, aripiprazole) which have evidence for both mood stabilization and anxiety in bipolar disorder 4
- Short-term benzodiazepine for acute anxiety (though guidelines note these may cause disinhibition in younger patients) 4
The safest approach is to optimize lithium levels first (target 0.8-1.0 mEq/L), then reassess whether mirtazapine increase is still needed after achieving better mood stabilization.